Elanco Animal Health (NYSE:ELAN) Releases FY 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 1.100-1.160 for the period, compared to the consensus estimate of 1.070. The company issued revenue guidance of $5.1 billion-$5.1 billion, compared to the consensus revenue estimate of $5.1 billion. Elanco Animal Health also updated its Q3 2026 guidance to 0.190-0.220 EPS.

Analyst Ratings Changes

Several brokerages have recently commented on ELAN. Citigroup upped their price objective on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. UBS Group raised their target price on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday. TD Cowen boosted their price target on shares of Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. Finally, Morgan Stanley raised their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Elanco Animal Health has a consensus rating of “Moderate Buy” and an average price target of $29.09.

Elanco Animal Health Stock Down 6.6%

Shares of NYSE:ELAN traded down $1.60 during trading hours on Friday, reaching $22.60. The stock had a trading volume of 13,454,645 shares, compared to its average volume of 5,531,224. The stock has a market capitalization of $11.29 billion, a price-to-earnings ratio of -55.23, a P/E/G ratio of 1.73 and a beta of 1.67. The firm’s 50 day moving average is $24.73 and its 200-day moving average is $24.10. Elanco Animal Health has a 1 year low of $16.15 and a 1 year high of $27.98. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.12% and a negative net margin of 3.96%.The business had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. During the same quarter in the prior year, the business posted $0.26 EPS. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Research analysts predict that Elanco Animal Health will post 1.1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Elanco Animal Health news, CEO Jeffrey N. Simmons acquired 4,971 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were purchased at an average price of $20.09 per share, with a total value of $99,867.39. Following the completion of the acquisition, the chief executive officer directly owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. The trade was a 2.98% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Rajeev A. Modi bought 4,911 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were bought at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the transaction, the insider directly owned 160,812 shares in the company, valued at approximately $3,272,524.20. This represents a 3.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 1.14% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Elanco Animal Health

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP raised its holdings in Elanco Animal Health by 1.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 25,082,545 shares of the company’s stock valued at $567,622,000 after acquiring an additional 373,869 shares during the last quarter. UBS Group AG raised its holdings in shares of Elanco Animal Health by 56.7% in the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after purchasing an additional 5,961,457 shares during the period. Fuller & Thaler Asset Management Inc. grew its holdings in shares of Elanco Animal Health by 16.1% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 5,771,622 shares of the company’s stock worth $130,612,000 after purchasing an additional 799,745 shares during the period. Invesco Ltd. increased its position in Elanco Animal Health by 336.0% during the 4th quarter. Invesco Ltd. now owns 4,789,037 shares of the company’s stock worth $108,376,000 after purchasing an additional 3,690,735 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after buying an additional 2,445,872 shares in the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.